Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
As cancer is becoming more and more a chronic disease, a large proportion of patients is confronted with devastating side effects of certain anti-cancer drugs. The most common neurological complications are painful peripheral neuropathies. Chemotherapeutics that interfere with microtubules, including plant-derived vinca-alkaloids such as vincristine, can cause these chemotherapy-induced peripheral neuropathies (CIPN). Available treatments focus on symptom alleviation and pain reduction rather than prevention of the neuropathy. The aim of this study was to investigate the potential of specific histone deacetylase 6 (HDAC6) inhibitors as a preventive therapy for CIPN using multiple rodent models for vincristine-induced peripheral neuropathies (VIPN). HDAC6 inhibition increased the levels of acetylated α-tubulin in tissues of rodents undergoing vincristine-based chemotherapy, which correlates to a reduced severity of the neurological symptoms, both at the electrophysiological and the behavioral level. Mechanistically, disturbances in axonal transport of mitochondria is considered as an important contributing factor in the pathophysiology of VIPN. As vincristine interferes with the polymerization of microtubules, we investigated whether disturbances in axonal transport could contribute to VIPN. We observed that increasing α-tubulin acetylation through HDAC6 inhibition restores vincristine-induced defects of axonal transport in cultured dorsal root ganglion neurons. Finally, we assured that HDAC6-inhibition offers neuroprotection without interfering with the anti-cancer efficacy of vincristine using a mouse model for acute lymphoblastic leukemia. Taken together, our results emphasize the therapeutic potential of HDAC6 inhibitors with beneficial effects both on vincristine-induced neurotoxicity, as well as on tumor proliferation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403 · cited 2×
“These unique features allow HDAC6 to interact with substrates other than histones, including α-tubulin (Hubbert et al., 2002; Zhang et al., 2003).”
Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A
Züchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali, E. L., Zappia, M., Nelis, E., Patitucci, A., Senderek, J., et al. (2004) · Nature Genetics · doi:10.1038/ng1341 · Cited by 1,572 · cited 2×
“the mitochondrial GTPase mitofusin-2 (MFN2), a protein associated with CMT2A (Bobylev et al., 2017; Züchner et al., 2004).”
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., Colvin, L. A., & Fallon, M. (2014) · Pain · doi:10.1016/j.pain.2014.09.020 · Cited by 1,555 · cited 1×
“Chemotherapy-induced peripheral neuropathies are the most common neurological side effects of anti-cancer treatments with an incidence of up to 80% (Cavaletti et al., 2011; Seretny et al., 2014).”
Microtubule assembly, organization and dynamics in axons and dendrites
Conde, C., & Cáceres, A. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2631 · Cited by 1,086 · cited 1×
“Microtubule dynamics is also of pivotal importance in post-mitotic neurons (Conde et al., 2009; Stanton et al., 2011).”
Microtubule Acetylation Promotes Kinesin-1 Binding and Transport
Reed, N. A., Cai, D., Blasius, T. L., Jih, G. T., Meyhofer, E., Gaertig, J., & Verhey, K. J. (2006) · Current Biology · doi:10.1016/j.cub.2006.09.014 · Cited by 919
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801 · cited 1×
“We validated these findings using a second HDAC6-specific inhibitor, Tubastatin A (Butler et al., 2010), emphasizing the specific contribution of HDAC6 to the assessment of VIPN (Fig.”
Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770 · cited 1×
“Unlike conventional histone deacetylases, HDAC6 is mostly localized in the cytoplasm, has a duplication of its catalytic deacetylase domain and a poly-ubiquitin associated zinc finger domain (Grozinger et al., 1999).”
BackgroundHDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 2×
“These unique features allow HDAC6 to interact with substrates other than histones, including α-tubulin (Hubbert et al., 2002; Zhang et al., 2003).”
Agliano, A., Martin‐Padura, I., Mancuso, P., Marighetti, P., Rabascio, C., Pruneri, G., Shultz, L. D., & Bertolini, F. (2008) · International Journal of Cancer · doi:10.1002/ijc.23772 · Cited by 163 · cited 4×
“Furthermore, vincristine-induced neurotoxicity was completely absent in animals co-treated with an HDAC6 inhibitor in comparison to animals receiving only vincristine, while the presence of ALL per se induced no neurological complications (Fig.”
Influential
Cited by
HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells
Yu, H., Lu, S., Gasior, K., Singh, D., Vazquez-Sanchez, S., Tapia, O., Toprani, D., Beccari, M. S., Yates, J. R., Da Cruz, S., et al. (2021) · Science · doi:10.1126/science.abb4309 · Cited by 353
Fazal, R., Boeynaems, S., Swijsen, A., De Decker, M., Fumagalli, L., Moisse, M., Vanneste, J., Guo, W., Boon, R., Vercruysse, T., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106177 · Cited by 108
“Mutations in TARDBP , the gene encoding the TDP-43 protein are a cause of familial ALS, and in rare cases also of ALS-FTD or FTD (Kabashi et al , 2008; Sreedharan et al , 2008; Van Deerlin et al , 2008; Lemmens et al , 2009; Borroni et al , 2009; Caroppo et al , 2016).”
InfluentialAxon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy
Coleman, M. P. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01297-6 · Cited by 33
“Possible methods include boosting fast axonal transport by inhibition of p38 MAPK [107], a strategy that has been effective in animal models [108], or by HDAC inhibition [109], or alternatively miRNA or ASO based strategies to influence local translation [110].”
Method
Metadata
- Authors
- Van Helleputte, L., Kater, M., Cook, D. P., Eykens, C., Rossaert, E., Haeck, W., Jaspers, T., Geens, N., Vanden Berghe, P., Gysemans, C., Mathieu, C., Robberecht, W., Van Damme, P., Cavaletti, G., Jarpe, M., & Van Den Bosch, L.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 111
- Pages
- 59-69
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2780627695
- Cited by
- 66
- References
- 10
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. https://app.cochat.ai/papers/10.1016/j.nbd.2017.11.011
- The paper
- Van Helleputte, L., Kater, M., Cook, D. P., Eykens, C., Rossaert, E., Haeck, W., Jaspers, T., Geens, N., Vanden Berghe, P., Gysemans, C., Mathieu, C., Robberecht, W., Van Damme, P., Cavaletti, G., Jarpe, M., & Van Den Bosch, L. (2018). Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2017.11.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.